Abstract
Mouse monoclonal antibodies and rabbit sntisera against human prostate specific antigen (PA) were produced. A double antibody sandwich enzyme immunoassay system was developed for serum PA determination using these monoclonal and polyclonal antibodies. The assay sensitivity is I ng per ml of serum. An initial clinical study indicates that serum PA levels were specifically high in patients with progressive prostate cancer. The new EIA method offers great potential for clinical management of prostate cancer.